GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » Cash Conversion Cycle

Genomma Lab InternacionalB de CV (Genomma Lab InternacionalB de CV) Cash Conversion Cycle : 92.95 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Genomma Lab InternacionalB de CV's Days Sales Outstanding for the three months ended in Mar. 2024 was 89.5.
Genomma Lab InternacionalB de CV's Days Inventory for the three months ended in Mar. 2024 was 119.54.
Genomma Lab InternacionalB de CV's Days Payable for the three months ended in Mar. 2024 was 116.09.
Therefore, Genomma Lab InternacionalB de CV's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 92.95.


Genomma Lab InternacionalB de CV Cash Conversion Cycle Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Cash Conversion Cycle Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120.05 111.86 128.35 123.69 99.82

Genomma Lab InternacionalB de CV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.41 119.41 110.87 115.03 92.95

Competitive Comparison of Genomma Lab InternacionalB de CV's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Cash Conversion Cycle falls into.



Genomma Lab InternacionalB de CV Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Genomma Lab InternacionalB de CV's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=82.69+114.28-97.15
=99.82

Genomma Lab InternacionalB de CV's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=89.5+119.54-116.09
=92.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Genomma Lab InternacionalB de CV Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV (Genomma Lab InternacionalB de CV) Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovalí Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.